43 filings
8-K
Audentes Therapeutics, Inc.
15 Jan 20
Astellas Completes Acquisition of Audentes Therapeutics
10:03am
8-K
Audentes Therapeutics, Inc.
16 Dec 19
Departure of Directors or Certain Officers
6:51am
8-K
Audentes Therapeutics, Inc.
3 Dec 19
Astellas Enters into Definitive Agreement to
12:00am
8-K
Audentes Therapeutics, Inc.
7 Nov 19
Results of Operations and Financial Condition
4:06pm
8-K
Audentes Therapeutics, Inc.
8 Oct 19
Other Events
9:54pm
8-K
h5t7er f4b
6 Aug 19
Results of Operations and Financial Condition
4:06pm
8-K
v9qelmfpxxc0482j2
28 Jun 19
Departure of Directors or Certain Officers
4:00pm
8-K
3w29c6
7 Jun 19
Departure of Directors or Certain Officers
4:30pm
8-K
noz4r5u4drqkod12up
29 May 19
Departure of Directors or Certain Officers
4:02pm
8-K
xsml8uh 1kjbtf
7 May 19
Results of Operations and Financial Condition
4:03pm
8-K
7xh1p
1 May 19
New data include 48 weeks of follow-up for six treated patients in dose Cohort 1 and 24 weeks for three treated patients in dose Cohort 2
2:15pm
8-K
13t8ygr
8 Apr 19
Other Events
7:11am
8-K
x85xp5h6p53iuxkos0q
27 Feb 19
Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update
12:00am
8-K
ix11rgse5vf9w0vm1
6 Nov 18
Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
12:00am
8-K
qpa jqa85ryz9v
11 Oct 18
Audentes Therapeutics Announces Pricing of Public Offering of Common Stock
4:24pm
8-K
t4fxdu246iiog2op8d
5 Oct 18
Regulation FD Disclosure
8:05am
8-K
06q1dm1
7 Aug 18
Results of Operations and Financial Condition
6:05am
8-K
b2n2vxs519aiqn 2kjqk
8 Jun 18
Submission of Matters to a Vote of Security Holders
5:15pm
8-K
o8y5he e8sr
16 May 18
Significant improvements in neuromuscular and respiratory function at 24-week timepoint
11:31am
8-K
aor6zml9y2e5ylx foxw
9 May 18
Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
4:16pm